Skip to main content
. Author manuscript; available in PMC: 2021 Aug 6.
Published in final edited form as: J Allergy Clin Immunol. 2021 Feb;147(2):428–438. doi: 10.1016/j.jaci.2020.12.633

FIG 2.

FIG 2.

The proportion of monogenic IEI amenable to different clinical management strategies (n = 452). A clinical management strategy can be adopted for every IEI, and for most of these conditions, several treatment strategies exist. These are variably instituted, depending on disease severity, specific disease complications, and other individual patient factors. Further details regarding therapies for each monogenic IEI are available in Table E1.